Despite the celebrity status “miracle” weight loss drugs like Ozempic and Wegovy have gained recently, it appears most Americans are not jumping at the chance to use them. A recent national survey found people strongly opposed using injectable weight loss drugs instead of making a diet change.

Drugs like Wegovy may trim your waistline but not medical costs, according to an analysis of U.S. health insurance claims shared with Reuters.

Here's what to know about weight loss drugs such as Wegovy and Zepbound. CR helps you decide whether semaglutide or tirzepatide is right for you.

As the popularity of GLP-1 meds like Wegovy and Zepbound grows, fewer Americans are turning to weight-loss surgeries to trim their waistlines, a new report finds.

Companies are figuring out how to cater to consumers using GLP-1 drugs, such as Ozempic.

The findings spell an uncertain future for hospitals and clinics that derive a significant portion of their revenues from obesity procedures.

Prescriptions of this GLP-1 class of diabetes and weight-loss medications more than doubled between 2022 and 2023, a new tally finds. "In contrast, there was a 25.6% decrease in patients undergoing metabolic bariatric surgery" during the same time period,